Bibliothèque de L'IMIST/CNRST

Part 1. Introduction -- 1. HSCT: Historical perspective -- 2. The EBMT: History, present and future -- 3. The role of unrelated donor registries in HSCT -- 4. The HSCT Unit -- 5. JACIE accreditation of HSCT programs -- 6. Statistical methods in HSCT and Cellular Therapies -- Part 2. Biological aspects -- 7. Biological properties of HSC: scientific basis for HSCT -- 8. Biological properties of cells other than HSC -- 9. Histocompatibility -- 10. Clinical and biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization -- Part 3. Methodology and clinical aspects -- 11. Evaluation and counselling of candidates -- 12. Donor selection for adults and pediatrics -- 13. Conditioning -- 14. Bone marrow harvesting for HSCT -- 15. Mobilization and collection of HSC -- 16. Collection of HSC in children -- 17. Processing, cryopreserving, and controlling the quality of HSCs -- 18. Procurement and management of cord blood -- 19. Graft manipulation -- 20. Documentation of engraftment and chimerism after HSCT -- 21. Short and long-term controls after HSCT -- Part 4. General management of the patient -- 22. Vascular access -- 23. Transfusion support -- 24. Nutritional support -- 25. GVHD prophylaxis (immunosuppression) -- 26. Management ATG (SIRS) -- 27. Infections control and isolation procedures -- 28. General management of the patient; Specific aspects of children -- 29. Vaccinations -- 30. Psychological morbidity and support -- 31. Clinical relevant drug interactions in HSCT -- 32. Role of nursing in HSCT -- 33. Ethical issues in HSCT -- 34. Quality of life assessment after HSCT for pediatric and adults -- Part 5. HSCT complications and management -- 35. Neutropenic fever -- 36. Bacterial infections -- 37. Invasive fungal infections -- 38. Viral infections -- 39. Other life-threatening infections -- 40. Bleeding and thrombotic complications -- 41. Graft failure -- 42. Early complications of endothelial origin -- 43. Acute Graft-versus-Host Disease -- 44. Chronic Graft-versus-Host Disease -- 45. Post-transplant lymphoproliferative syndromes -- 46. Iron overload -- 47. Secondary neoplasia (other than PTLPS) -- Part 6. Specific organ complications -- 48. Ocular and oral complications -- 49. Hepatic complications -- 50. Gastrointestinal complications -- 51. Hemorrhagic cystitis and renal dysfunction -- 52. Non-infectious pulmonary complications -- 53. Neurological complications -- 54. Skin, hair and musculoskeletal complications -- 55. Cardiovascular diseases and metabolic syndrome -- 56. Endocrine disorders, fertility and sexual health -- Part 7. Prevention and management of relapse -- 57. Monitoring MRD in ALL and AML -- 58. Preventing/treating relapse with drugs -- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion -- 60. Cellular therapy with engineered T cells, efficacy and side effects -- 61. Mechanisms of Immune resistance -- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells -- Part 8. Specific modalities of HSCT and management -- 63. At-home HSCT -- 64. Umbilical cord blood transplantation in children and adults -- 65. Haploidentical HSCT -- 66. Photopheresis in adults and pediatrics -- 67. Overweight and obese patients -- 68. HSCT in elderly patients -- Part 9. Indications and results -- 69. Acute Myeloid Leukemia in adults -- 70. Acute Myeloid Leukemia in children -- 71. Acute Lymphoblastic Leukemia in adults -- 72. Acute lymphoblastic leukemia in children and adolescents -- 73. Myelodysplastic syndromes -- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia -- 75. Myelodysplastic/myeloproliferative neoplasms -- 76. Myeloproliferative neoplasms -- 77. Severe aplastic anemia and PNH -- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes -- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia) -- 80. Multiple myeloma -- 81. Systemic light chain amyloidosis -- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins -- 83. Follicular lymphoma -- 84. Chronic lymphocytic leukemia -- 85. Diffuse large B cell lymphoma -- 86. Mantle cell lymphoma -- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV -- 88. Classical Hodgkin's lymphoma -- 89. Primary immunodeficiencies -- 90. Inborn error of metabolism and osteopetrosis -- 91. Autoimmune disease -- 92. Solid tumors.